raxivanol 20 mg filmtabletta
anfarm hellas s.a. - rivaroxaban -
orladeyo
biocryst ireland limited - berotralstat dihydrochloride - angioödéma, örökletes - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.
anlamyl 10 mg/ml szirup
anfarm hellas s.a. - lakozamidot -
leflunomide mylan 10 mg filmtabletta
generics uk limited - leflunomid -
leflunomide mylan 20 mg filmtabletta
generics uk limited - leflunomid -
leflunomide mylan 100 mg filmtabletta
generics uk limited - leflunomid -
symkevi
vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cisztás fibrózis - egyéb légzőszervi termékek - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.
verzenios
eli lilly nederland b.v. - abemaciclib - mellnövekedés - daganatellenes szerek - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
farmorubicin rd 10 mg injekció
farmorubicin rd 50 mg injekció